03000nas a2200421 4500000000100000008004100001653001100042653001100053653000900064653001600073653001700089653002600106653002600132653007300158653003100231653002000262653002700282653002100309653003400330653002500364100002200389700001100411700001800422700001200440700001400452700001400466700001500480700001200495700001200507700001500519700001400534245011800548250001500666300001000681490000800691520182800699020005102527 2015 d10aFemale10aHumans10aMale10aMiddle Aged10aRisk Factors10aSocioeconomic Factors10aCost-Benefit Analysis10aCardiovascular Diseases/economics/ epidemiology/prevention & control10aGreat Britain/epidemiology10aLife Expectancy10aModels, Cardiovascular10aMorbidity/trends10aPrimary Prevention/ standards10aSurvival Rate/trends1 aTunstall-Pedoe H.1 aFox K.1 aWoodward Mark1 aFord I.1 aLewsey J.1 aLawson K.1 aRitchie L.1 aWatt G.1 aKent S.1 aNeilson M.1 aBriggs A.00aA cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation a2014/10/18 a201-80 v1013 a

OBJECTIVES: A policy model is a model that can evaluate the effectiveness and cost-effectiveness of interventions and inform policy decisions. In this study, we introduce a cardiovascular disease (CVD) policy model which can be used to model remaining life expectancy including a measure of socioeconomic deprivation as an independent risk factor for CVD. DESIGN: A state transition model was developed using the Scottish Heart Health Extended Cohort (SHHEC) linked to Scottish morbidity and death records. Individuals start in a CVD-free state and can transit to three CVD event states plus a non-CVD death state. Individuals who have a non-fatal first event are then followed up until death. Taking a competing risk approach, the cause-specific hazards of a first event are modelled using parametric survival analysis. Survival following a first non-fatal event is also modelled parametrically. We assessed discrimination, validation and calibration of our model. RESULTS: Our model achieved a good level of discrimination in each component (c-statistics for men (women)-non-fatal coronary heart disease (CHD): 0.70 (0.74), non-fatal cerebrovascular disease (CBVD): 0.73 (0.76), fatal CVD: 0.77 (0.80), fatal non-CVD: 0.74 (0.72), survival after non-fatal CHD: 0.68 (0.67) and survival after non-fatal CBVD: 0.65 (0.66)). In general, our model predictions were comparable with observed event rates for a Scottish randomised statin trial population which has an overlapping follow-up period with SHHEC. After applying a calibration factor, our predictions of life expectancy closely match those published in recent national life tables. CONCLUSIONS: Our model can be used to estimate the impact of primary prevention interventions on life expectancy and can assess the impact of interventions on inequalities.

 a1468-201X (Electronic)
1355-6037 (Linking)